Cemiplimab (Libtayo) shows benefit in basal call carcinoma

Study found objective response rate for patients with locally advanced disease was 29%, with an estimated duration of response exceeding one year in 85% of responders.

SPS commentary:

Currently in the UK, cemiplimab is licensed only as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma, who are not candidates for curative surgery or curative radiation.


Pharmaceutical Journal